SunWay Biotech Co

SunWay Biotech Co Receivables

The Accounts Receivable of SunWay Biotech Co (1271.TWO) as of Nov 16, 2026 is 278.41 M TWD. In the previous year, Accounts Receivable was 212.82 M TWD — a change of 30.82% (higher).

Receivables

278.41 MTWD

YoY

30.82%

Last updated:

Accounts Receivable of SunWay Biotech Co is 2024 278.41 M TWD. Accounts Receivable of SunWay Biotech Co was 2023 212.82 M TWD. It decreases by 30.82% higher compared to the previous year.

The SunWay Biotech Co Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
28.91 M TWD
Jan 1, 2018
47.65 M TWD
Jan 1, 2019
43.98 M TWD
Jan 1, 2020
45.97 M TWD
Jan 1, 2021
102.45 M TWD
Jan 1, 2022
50.81 M TWD
Jan 1, 2023
212.82 M TWD
Jan 1, 2024
278.41 M TWD
The SunWay Biotech Co Receivables history
YEARReceivablesYoY
278.41 MTWD+30.82%
212.82 MTWD+318.86%
50.81 MTWD-50.40%
102.45 MTWD+122.86%
45.97 MTWD+4.53%
43.98 MTWD-7.70%
47.65 MTWD+64.83%
28.91 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co., Ltd. generates revenue through the research, development, manufacture, and sale of red yeast health food products. The company's main products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which target digestive health, bacterial ecology regulation, immunity, and allergy management. These products are sold in both domestic and overseas markets, catering to consumers seeking natural health solutions. The firm focuses on health food segments where digestive and immune support are key consumer needs. The company's product portfolio emphasizes specific strains like Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their functional benefits in digestion and immune regulation. These health foods are distributed across domestic and international channels, targeting health-conscious consumers who prioritize natural remedies. SunWay Biotech leverages its research-driven approach to position these products in the health food market. SunWay Biotech Co., Ltd. operates within the health food industry, focusing on products that address digestive and immune health through natural ingredients. Its offerings are designed to improve bacterial ecology in the digestive tract and regulate immunity and allergies, appealing to a segment of consumers interested in preventive health solutions. The company's domestic and overseas market strategy ensures broad reach for its specialized health food products. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Accounts Receivable of SunWay Biotech Co is 278.41 M TWD in 2024.

Accounts Receivable of SunWay Biotech Co changed from 212.82 M TWD to 278.41 M TWD, representing a 30.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's SunWay Biotech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co